275 related articles for article (PubMed ID: 30339279)
1. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
5. Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma.
Oliveira DS; Mesquita JL; Garcia YDO; Rosales YMZ; Lemes RPG; Rocha Filho FD; Fernandes PFCBC; Duarte PMA; Pitombeira MDS; Duarte FB
Rev Assoc Med Bras (1992); 2019 Aug; 65(7):934-936. PubMed ID: 31389500
[No Abstract] [Full Text] [Related]
6. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
7. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Maruyama D; Terui Y; Yamamoto K; Fukuhara N; Choi I; Kuroda J; Ando K; Hattori A; Tobinai K
Jpn J Clin Oncol; 2020 Oct; 50(11):1265-1273. PubMed ID: 32776097
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
Ramchandren R; Domingo-Domènech E; Rueda A; Trněný M; Feldman TA; Lee HJ; Provencio M; Sillaber C; Cohen JB; Savage KJ; Willenbacher W; Ligon AH; Ouyang J; Redd R; Rodig SJ; Shipp MA; Sacchi M; Sumbul A; Armand P; Ansell SM
J Clin Oncol; 2019 Aug; 37(23):1997-2007. PubMed ID: 31112476
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
10. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
12. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
Gunes AK; Demir I; Pehlivan M
J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
Liput J; Guler E; Smith DA; Tirumani SH; Hoimes C; Caimi PF; Ramaiya NH
J Comput Assist Tomogr; 2020; 44(4):619-626. PubMed ID: 32558769
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.
Amraee A; Evazi MR; Shakeri M; Roozbeh N; Ghazanfarpour M; Ghorbani M; Ansari J; Darvish L
Clin Transl Oncol; 2019 Aug; 21(8):1093-1103. PubMed ID: 30739242
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience.
Dada R; Zabani Y
J Oncol Pharm Pract; 2019 Oct; 25(7):1586-1589. PubMed ID: 30253728
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM
Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.
Kawasaki A; Hatake K; Matsumura I; Izutsu K; Hoshino T; Akamatsu A; Kakuuchi A; Tobinai K
Int J Hematol; 2024 Jun; 119(6):667-676. PubMed ID: 38521840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
